This article was originally published in The Gray Sheet
Letter of intent to acquire Genetic Laboratorires Wound Care for stock valued at $3.6 mil. is announced May 12. Under the terms of the deal, 0.7 shares of Derma Sciences common stock, which closed at 2-1/8 on May 11, would be exchanged for each of St. Paul-based Genetic Laboratories' 2.4 mil. outstanding shares. The companies expect to sign a definitive agreement by the end of May and close the deal by September....
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.